Medline Inc. (NASDAQ:MDLN) Faces FDA Scrutiny and Stock Decline Amidst Legal Investigation

• Medline Inc. is currently under legal investigation following a U.S. Food and Drug Administration (FDA) warning regarding significant manufacturing practice violations.
• The FDA warning and subsequent second-quarter earnings report led to significant drops in Medline's stock price, impacting investor confidence.
• Despite exceeding Q2 earnings and revenue estimates, Medline lowered its full-year adjusted EBITDA guidance, prompting analysts to reduce their price targets.

Medline Inc. (NASDAQ:MDLN) is a major healthcare company that manufactures and distributes medical supplies. It operates in a competitive market alongside other large distributors. The company is currently under investigation by law firm Kessler Topaz Meltzer & Check, LLP for potential violations of federal securities laws that protect investors.

The investigation follows a U.S. Food and Drug Administration (FDA) warning letter published on June 2, 2026. The letter detailed "significant violations of Current Good Manufacturing Practice regulations." Specifically, the FDA noted that Medline "failed to thoroughly investigate any unexplained discrepancy or failure of a batch."

After the FDA news, Medline's stock price declined over 7%. As highlighted by Reuters, this was the second action against the company in two months for quality violations. The stock saw a further significant drop of over 12% on August 5, 2026, after its second-quarter results were released.

On August 5th, Medline lowered its full-year adjusted EBITDA guidance, which is a forecast of its operational profitability. However, the company's quarterly results beat expectations. It reported earnings per share of $0.50, surpassing the $0.35 estimate, and revenue of $7.69 billion, which was above the estimated $7.52 billion.

Following the news, Stifel Nicolaus lowered its price target for Medline to $45. A price target is an analyst's projection of a stock's future price. At the time, this represented a potential upside of 26.62% from its trading price of $35.54. The company has a market capitalization of approximately $29.79 billion.